Universität zu Köln

Eichhorst, Barbara, Fuerstenau, Moritz and Hallek, Michael (2019). Relapsed disease and aspects of undetectable MRD and treatment discontinuation. Hematol.-Am. Soc. Hematol. Educ. Program. S. 482 - 490. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1520-4383

Full text not available from this repository.

Abstract

Continuous treatment vs fixed duration of monotherapies and combinations of targeted agents are treatment options in relapsed chronic lymphocytic leukemia. The optimal choice of relapse treatment is dependent on the prior frontline therapy, duration of remission after frontline, genetic markers, and patients' condition, including age and comorbidities. Combination therapies may result in deep responses with undetectable minimal residual disease (uMRD). Although uMRD is an excellent predictive marker for disease progression, it is rarely used in clinical practice and needs additional evaluation in clinical trials before discontinuation of therapy should be guided according to uMRD.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuerstenau, Moritz UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-124963
Journal or Publication Title:	Hematol.-Am. Soc. Hematol. Educ. Program
Page Range:	S. 482 - 490
Date:	2019
Publisher:	AMER SOC HEMATOLOGY
Place of Publication:	WASHINGTON
ISSN:	1520-4383
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CHRONIC LYMPHOCYTIC-LEUKEMIA; FLOW-CYTOMETRY; OPEN-LABEL; ACALABRUTINIB ACP-196; CLONAL EVOLUTION; FREE SURVIVAL; FOLLOW-UP; IBRUTINIB; CLL; VENETOCLAX Multiple languages Education, Scientific Disciplines; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/12496